Immune booster combined with checkpoint blocker improves survival in metastatic melanoma

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer if they simultaneously received an immune stimulant. This image shows F. Stephen Hodi, M.D., director of the Melanoma Treatment Center and director of the Center for Immuno-Oncology at Dana-Farber.

http://ift.tt/1AgF6kG